T lymphocyte activation pathways

T lymphocyte activation pathways represent the complex network of intracellular signaling events that dictate the transition of T cells from a naive or resting state to an active effector state. This process is primarily initiated by the T-cell receptor (TCR) recognizing an antigen-MHC complex, which constitutes Signal 1 (StatPearls, NBK554481). For full activation and to prevent anergy, a second Signal 2 is required, typically provided by co-stimulatory molecules like CD28 interacting with B7 ligands on antigen-presenting cells (Nature Reviews Immunology, nri.2017.117). These signals trigger a cascade of biochemical events, including the activation of kinases like Lck and ZAP-70, which lead to the mobilization of calcium and the activation of transcription factors such as NFAT and NF-kappaB (Frontiers in Immunology, 10.3389/fimmu.2020.01138). These pathways are essential for mounting an effective immune response against pathogens and tumors, but their dysregulation is a hallmark of autoimmune diseases and transplant rejection. Consequently, these pathways are major therapeutic targets; drugs may either suppress activation to treat inflammation or enhance it to combat cancer (Nature Reviews Immunology, s41577-020-0306-5). However, modulating these broad pathways requires careful management due to risks of systemic immunosuppression or hyper-inflammation.

Other names

T cell activationT-cell receptor signaling pathwayTCR signaling cascadeT lymphocyte signaling

Inhibition of calcineurin, mTOR, or specific co-stimulatory/inhibitory receptors to modulate T cell activation and effector function (Nature Reviews Immunology, s41577-020-0306-5).